Drug Profile
ICE 3 - Iceni Pharmaceuticals
Alternative Names: ICE3Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer Iceni Pharmaceuticals
- Class Antineoplastics; Cyclic peptides; Small molecules; Venoms
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Breast-cancer(Combination therapy) in United Kingdom
- 07 Jul 2016 Preclinical trials in Breast cancer (Combination therapy) in United Kingdom (unspecified route)